IMG-007
Immunological, Autoimmune and Inflammatory Diseases (e.g., Alopecia Areata)
Phase 2Active
Key Facts
Indication
Immunological, Autoimmune and Inflammatory Diseases (e.g., Alopecia Areata)
Phase
Phase 2
Status
Active
Company
About ImageneBio
ImageneBio is a private, clinical-stage biotech focused on developing a potential best-in-class anti-OX40 monoclonal antibody, IMG-007, for immunological and inflammatory diseases. The company is led by an experienced management team with a track record in drug development and is backed by notable venture capital investors from its board. With a single, differentiated asset in clinical development, the company's near-term value is heavily tied to the success of IMG-007 in treating conditions like alopecia areata and other undisclosed indications.
View full company profile